Skip to main content
. 2015 Nov 23;37(2):255–263. doi: 10.1038/aps.2015.85

Figure 6.

Figure 6

Aconine inhibits RANKL-induced NFATc1 activation. (A) RAW264.7 cells were pretreated with varying concentrations of aconine for 2 h and then treated with RANKL (100 ng/mL) for 24 h. NFATc1 mRNA levels were analyzed using real-time PCR. (B) RAW264.7 cells that were stably transfected with an NFATc1 luciferase reporter construct were pretreated with varying concentrations of aconine and the NFAT inhibitor, CsA, for 30 min and then treated with RANKL (100 ng/mL) for 8 h. Mean±SEM. n=3. bP<0.05, cP<0.01 vs control; eP<0.05, fP<0.01 vs only RANKL-treated cells.